Osteosarcoma, while rare, is the most common primary bone cancer in children and adolescents, accounting for approximately 10% of new pediatric cancer diagnoses in the
CELLINK, a global leader in developing and delivering life-science solutions, has joined forces with Lonza, the Swiss Chemicals and Biotechnology Company, to offer a comprehensive